Company: RPTX
Filing Date: 2025-04-29
Form Type: DEFA14A
Source: 0001193125-25-103791
Chunk: 1

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEFA14A
Chunk 1
---
, please call (888) 464-5457.Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mailcopy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for the deadline to submit voting instructions, as applicable, and this year’s meeting, you must make this request on or before 5:00 PM, Eastern Time, on June 6, 2025. SEE REVERSE FOR FULL AGENDA Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-KImportant Notice Regarding the Availability of Proxy Materials for the Shareholders Meeting To Be Held On June 17, 2025 For Shareholders of Record as of April 21, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/RPTX Call: 1-866-648-8133Email: paper@investorelections.com * If requesting material by e-mail,please send a blank e-mailwith the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mailrequesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved

Repare Therapeutics Inc. Annual Meeting of Shareholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH OF THE DIRECTOR NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSALS 2 AND 3 PROPOSAL 1. To elect the four nominees of our board of directors, to our board of directors as Class II directors, each to hold office until our Annual Meeting of Shareholders in 2028 and until such director’s successor has been duly elected, or if sooner, until the director’s death, resignation or removal. 1.01 David Bonita, M.D. 1.02 Thomas Civik 1.03 Carol A. Schafer 1.04 Steven Stein, M.D. 2. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement. 3.